The Valley Desk

NCT03328078 · Interventional trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov